JP2020510073A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020510073A5 JP2020510073A5 JP2019550774A JP2019550774A JP2020510073A5 JP 2020510073 A5 JP2020510073 A5 JP 2020510073A5 JP 2019550774 A JP2019550774 A JP 2019550774A JP 2019550774 A JP2019550774 A JP 2019550774A JP 2020510073 A5 JP2020510073 A5 JP 2020510073A5
- Authority
- JP
- Japan
- Prior art keywords
- concentration
- composition according
- pharmaceutical composition
- dutetrabenazine
- determination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 14
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- MKJIEFSOBYUXJB-WEZHFFAMSA-N (3s,11bs)-3-(2-methylpropyl)-9,10-bis(trideuteriomethoxy)-1,3,4,6,7,11b-hexahydrobenzo[a]quinolizin-2-one Chemical compound C1CN2C[C@H](CC(C)C)C(=O)C[C@H]2C2=C1C=C(OC([2H])([2H])[2H])C(OC([2H])([2H])[2H])=C2 MKJIEFSOBYUXJB-WEZHFFAMSA-N 0.000 claims 11
- 238000004128 high performance liquid chromatography Methods 0.000 claims 9
- 229940125782 compound 2 Drugs 0.000 claims 8
- MKJIEFSOBYUXJB-HOCLYGCPSA-N (3S,11bS)-9,10-dimethoxy-3-isobutyl-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one Chemical compound C1CN2C[C@H](CC(C)C)C(=O)C[C@H]2C2=C1C=C(OC)C(OC)=C2 MKJIEFSOBYUXJB-HOCLYGCPSA-N 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 208000013403 hyperactivity Diseases 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 229960005333 tetrabenazine Drugs 0.000 claims 5
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 239000008186 active pharmaceutical agent Substances 0.000 claims 2
- 229950005031 deutetrabenazine Drugs 0.000 claims 2
- 229940088679 drug related substance Drugs 0.000 claims 2
- 206010008748 Chorea Diseases 0.000 claims 1
- 206010043118 Tardive Dyskinesia Diseases 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 208000012601 choreatic disease Diseases 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000004899 motility Effects 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022177578A JP2023010754A (ja) | 2017-03-15 | 2022-11-04 | デューテトラベナジンの類似体、その調製及び使用 |
| JP2024011974A JP7631572B2 (ja) | 2017-03-15 | 2024-01-30 | デューテトラベナジンの類似体、その調製及び使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762471484P | 2017-03-15 | 2017-03-15 | |
| US62/471,484 | 2017-03-15 | ||
| PCT/US2018/022562 WO2018170214A1 (en) | 2017-03-15 | 2018-03-15 | Analogs of deutetrabenazine, their preparation and use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022177578A Division JP2023010754A (ja) | 2017-03-15 | 2022-11-04 | デューテトラベナジンの類似体、その調製及び使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020510073A JP2020510073A (ja) | 2020-04-02 |
| JP2020510073A5 true JP2020510073A5 (enExample) | 2021-12-23 |
| JP7608050B2 JP7608050B2 (ja) | 2025-01-06 |
Family
ID=61873991
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019550774A Active JP7608050B2 (ja) | 2017-03-15 | 2018-03-15 | デューテトラベナジンの類似体、その調製及び使用 |
| JP2022177578A Pending JP2023010754A (ja) | 2017-03-15 | 2022-11-04 | デューテトラベナジンの類似体、その調製及び使用 |
| JP2024011974A Active JP7631572B2 (ja) | 2017-03-15 | 2024-01-30 | デューテトラベナジンの類似体、その調製及び使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022177578A Pending JP2023010754A (ja) | 2017-03-15 | 2022-11-04 | デューテトラベナジンの類似体、その調製及び使用 |
| JP2024011974A Active JP7631572B2 (ja) | 2017-03-15 | 2024-01-30 | デューテトラベナジンの類似体、その調製及び使用 |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US11813232B2 (enExample) |
| EP (1) | EP3596077A1 (enExample) |
| JP (3) | JP7608050B2 (enExample) |
| KR (2) | KR20200003791A (enExample) |
| CN (1) | CN110709398A (enExample) |
| AR (1) | AR111182A1 (enExample) |
| AU (2) | AU2018236336B2 (enExample) |
| BR (1) | BR112019018966A2 (enExample) |
| CA (1) | CA3056612A1 (enExample) |
| CL (1) | CL2019002629A1 (enExample) |
| CO (1) | CO2019011271A2 (enExample) |
| EA (1) | EA201992168A1 (enExample) |
| IL (1) | IL269132A (enExample) |
| MX (1) | MX2019010913A (enExample) |
| PE (1) | PE20191819A1 (enExample) |
| SG (1) | SG11201908477QA (enExample) |
| TW (1) | TWI772382B (enExample) |
| UA (1) | UA127052C2 (enExample) |
| WO (1) | WO2018170214A1 (enExample) |
| ZA (1) | ZA201906326B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11813232B2 (en) | 2017-03-15 | 2023-11-14 | Auspex Pharmaceuticals, Inc. | Analogs of deutetrabenazine, their preparation and use |
| WO2020123900A1 (en) | 2018-12-13 | 2020-06-18 | Auspex Pharmaceuticals, Inc. | Deutetrabenazine for the treatment of dyskinesia in cerebral palsy |
| WO2020165807A1 (en) * | 2019-02-14 | 2020-08-20 | Dr. Reddy's Laboratories Limited | Solid forms of deutetrabenazine and process for the preparation thereof |
| US12599598B2 (en) | 2020-06-10 | 2026-04-14 | Auspex Pharmaceuticals Llc | Osmotic dosage forms comprising deutetrabenazine and methods of use thereof |
| EP4153136B1 (en) * | 2020-06-10 | 2024-01-10 | Auspex Pharmaceuticals, Inc. | Osmotic dosage forms comprising deutetrabenazine and methods of use thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2081929T3 (da) | 2006-11-08 | 2013-04-15 | Neurocrine Biosciences Inc | Substituerede 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11B-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol-forbindelser og fremgangsmåder angående disse |
| CA2736409C (en) * | 2008-09-18 | 2017-07-11 | Auspex Pharmaceutical, Inc. | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| CA2801061A1 (en) | 2010-06-01 | 2011-12-08 | Auspex Pharmaceuticals, Inc. | Benzoquinolone inhibitors of vmat2 |
| WO2012081031A1 (en) * | 2010-12-15 | 2012-06-21 | Enaltec Labs Pvt. Ltd. | Process for preparing tetrabenazine |
| US9550780B2 (en) * | 2012-09-18 | 2017-01-24 | Auspex Pharmaceuticals, Inc. | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| CA2883641C (en) * | 2012-09-18 | 2021-09-14 | Auspex Pharmaceuticals, Inc. | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| CN105873589B (zh) | 2013-12-03 | 2019-11-01 | 奥斯拜客斯制药有限公司 | 制造苯并喹啉化合物的方法 |
| CN114767672A (zh) | 2015-03-06 | 2022-07-22 | 奥斯拜客斯制药有限公司 | 氘代丁苯那嗪或包含氘代丁苯那嗪的组合物 |
| US11813232B2 (en) | 2017-03-15 | 2023-11-14 | Auspex Pharmaceuticals, Inc. | Analogs of deutetrabenazine, their preparation and use |
-
2018
- 2018-03-15 US US15/922,329 patent/US11813232B2/en active Active
- 2018-03-15 UA UAA201910309A patent/UA127052C2/uk unknown
- 2018-03-15 KR KR1020197030354A patent/KR20200003791A/ko not_active Ceased
- 2018-03-15 SG SG11201908477Q patent/SG11201908477QA/en unknown
- 2018-03-15 MX MX2019010913A patent/MX2019010913A/es unknown
- 2018-03-15 PE PE2019001871A patent/PE20191819A1/es unknown
- 2018-03-15 KR KR1020227043234A patent/KR20230003308A/ko not_active Ceased
- 2018-03-15 TW TW107108832A patent/TWI772382B/zh active
- 2018-03-15 EP EP18715393.7A patent/EP3596077A1/en active Pending
- 2018-03-15 BR BR112019018966-1A patent/BR112019018966A2/pt not_active Application Discontinuation
- 2018-03-15 CN CN201880018609.8A patent/CN110709398A/zh active Pending
- 2018-03-15 EA EA201992168A patent/EA201992168A1/ru unknown
- 2018-03-15 CA CA3056612A patent/CA3056612A1/en active Pending
- 2018-03-15 AR ARP180100611A patent/AR111182A1/es not_active Application Discontinuation
- 2018-03-15 JP JP2019550774A patent/JP7608050B2/ja active Active
- 2018-03-15 WO PCT/US2018/022562 patent/WO2018170214A1/en not_active Ceased
- 2018-03-15 AU AU2018236336A patent/AU2018236336B2/en active Active
-
2019
- 2019-09-04 IL IL26913219A patent/IL269132A/en unknown
- 2019-09-13 CL CL2019002629A patent/CL2019002629A1/es unknown
- 2019-09-25 ZA ZA2019/06326A patent/ZA201906326B/en unknown
- 2019-09-25 US US16/582,362 patent/US11179386B2/en active Active
- 2019-10-10 CO CONC2019/0011271A patent/CO2019011271A2/es unknown
-
2021
- 2021-10-21 US US17/507,037 patent/US12502385B2/en active Active
- 2021-11-30 US US17/537,663 patent/US20220088006A1/en not_active Abandoned
-
2022
- 2022-05-18 AU AU2022203369A patent/AU2022203369B2/en active Active
- 2022-11-04 JP JP2022177578A patent/JP2023010754A/ja active Pending
-
2024
- 2024-01-30 JP JP2024011974A patent/JP7631572B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA200900264A1 (ru) | Композиции флибансерина и способ их приготовления | |
| JP2017537168A5 (enExample) | ||
| EP4011364A1 (en) | Methods and compositions for treatment of attention deficit disorder | |
| TW201929839A (zh) | 一種控釋藥物組合物及其製備方法 | |
| UY29890A1 (es) | Composiciones farmacéuticas sólidas que contienen pregabalina | |
| EA201892836A1 (ru) | Составы 2-[3-[4-амино-3-(2-фтор-4-феноксифенил)пиразол[3,4-d]пиримидин-1-ил]пиперидин-1-карбонил]-4-метил-4-[4-(оксетан-3-ил)пиперазин-1-ил]пент-2-еннитрила с модифицированным высвобождением | |
| NZ600129A (en) | Capsule formation of pirfenidone and pharmaceutically acceptable excipients | |
| IL278188B2 (en) | Sublingual formulation of riluzole | |
| JP2006504795A5 (enExample) | ||
| ES2546847T3 (es) | Formulaciones de un inhibidor de la Src/Abl | |
| RU2016103764A (ru) | Стабилизированные фармацевтические лекарственные формы, содержащие атрасентан | |
| AR045289A1 (es) | Forma de dosificacion oral de liberacion controlada que comprende 4-(2-di-n-propilaminoetil) - 2(3h)-indolona (ropi-nirol) y uso de dicha forma de dosificacion para la elaboracion de un medicamento | |
| JP2016530238A5 (enExample) | ||
| JP2020500164A5 (enExample) | ||
| JP2018530578A5 (enExample) | ||
| ATE505203T1 (de) | Pharmazeutische kombination aus aliskiren und valsartan | |
| Alam et al. | Mucoadhesive elementary osmotic pump tablets of trimetazidine for controlled drug delivery and reduced variability in oral bioavailability | |
| JP2014521641A5 (enExample) | ||
| AR066924A1 (es) | Formulacion de nevirapina de liberacion prolongada | |
| Dey et al. | Polymers derived from Xanthomonas campesteris and Cyamopsis tetragonolobus used as retardant materials for the formulation of sustained release floating matrix tablet of atenolol | |
| Davies et al. | The impact of sertraline co-administration on the pharmacokinetics of olanzapine: a population pharmacokinetic analysis of the STOP-PD | |
| Min et al. | Formulation and bioequivalence studies of choline alfoscerate tablet comparing with soft gelatin capsule in healthy male volunteers | |
| Mauceri et al. | Mucoadhesive drug delivery systems for oral chronic inflammatory mucosal diseases. The future is already present. A systematic review | |
| Cheng et al. | Tegoprazan dual and quadruple therapy for Helicobacter pylori eradication: a prospective, randomized controlled trial in Beijing, China | |
| JP2022540348A5 (enExample) |